Welcome to our dedicated page for Anebulo Pharmaceuticals news (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals stock.
Anebulo Pharmaceuticals, Inc. develops selonabant, a competitive antagonist at the human CB1 receptor, for acute cannabis-induced toxic effects. Company updates focus on clinical and regulatory progress for oral and intravenous selonabant, including work directed at acute cannabinoid intoxication and pediatric acute cannabis-induced toxicity.
Recurring ANEB news also includes operating and financial results, NIH/NIDA-supported research activity, common stock capital actions such as tender-offer results, shareholder voting matters, governance updates, and corporate-status disclosures related to listing and Exchange Act reporting obligations.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported Q2 FY2026 results and announced voluntary delisting from Nasdaq and planned SEC deregistration. The Board expects Nasdaq delisting effective Feb 27, 2026, and immediate suspension of SEC reporting upon Form 15 filing. Q2 operating expenses were $2.6M; net loss was $2.0M ($(0.05)/share). Cash and equivalents totaled $9.0M as of Dec 31, 2025, plus access to a $3.0M loan facility.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced its board approved a voluntary delisting from Nasdaq and planned deregistration with the SEC to suspend Exchange Act reporting obligations.
The company expects to file Form 25 on or about Feb 17, 2026 and expects the delisting to become effective Feb 27, 2026, with a Form 15 filing around Feb 27, 2026 if it certifies fewer than 300 shareholders of record.
The Board cited the cost and management burden of SEC reporting, Sarbanes-Oxley compliance, and related legal and audit expenses as primary reasons; post-delisting trading would be private sales or potentially on the OTC market.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced final results of its voluntary tender offer to purchase 300,000 shares of common stock at $3.50 per share, which expired January 26, 2026. The offer was oversubscribed with 4,907,881 shares tendered; Anebulo accepted 300,000 shares (including 134,306 odd lots) for an aggregate cost of approximately $1.05 million, excluding fees and expenses. The final proration factor was 3.47392%, and accepted shares represent about 0.73% of outstanding shares as of January 26, 2026. Payment and return of non-purchased shares will occur promptly and in cash without interest.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced preliminary results of its voluntary self-tender offer to purchase 300,000 shares of common stock at $3.50 per share, expiring January 26, 2026.
Based on a preliminary count by the depositary, 4,897,188 shares were properly tendered (excluding 10,868 by guaranteed delivery), the offer was oversubscribed, and Anebulo expects to accept 300,000 shares pro rata for an aggregate cash cost of approximately $1.05 million (excluding fees).
The preliminary proration factor is approximately 3.51542%, and the shares expected to be purchased represent about 0.73% of outstanding shares as of January 26, 2026; final numbers are subject to depositary confirmation.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced on December 22, 2025 that its Board will commence a voluntary self tender offer to purchase up to 300,000 shares at $3.50 per share in lieu of a previously proposed reverse stock split (proposed ratios: 1-for-2,500 to 1-for-7,500).
The Board said costs tied to fractional-share payments after the split—driven by holders opening multiple small accounts—now outweigh benefits, so the reverse split is abandoned and a tender offer will be filed on Schedule TO with the SEC. Tender documents will be distributed to stockholders and made available at www.sec.gov.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported Q1 FY2026 results and program updates on November 13, 2025. Key updates include first subjects dosed in a FDA-cleared Phase 1 single ascending dose (SAD) IV study of selonabant for acute cannabis-induced toxicity and a $994,300 second-year NIDA grant tranche to support the SAD study. The company cited a prior successful Phase 2 oral selonabant trial in adults and ongoing FDA collaboration for pediatric development. Corporate actions include a Board-approved proposed reverse stock split tied to a possible going-private transaction, with shareholder approval pending and a special meeting delayed by SEC comment resolution affected by a government shutdown. Q1 operating expenses were $2.3M, net loss $2.2M (loss per share $(0.05)), and cash of $10.4M with an additional $3.0M loan available.
Anebulo Pharmaceuticals (Nasdaq: ANEB) reported its Q4 and FY2025 financial results while announcing significant progress in its clinical programs. The company has initiated dosing in a Phase 1 single ascending dose (SAD) study of an intravenous formulation of selonabant, their lead drug candidate for treating acute cannabis-induced toxicity in children.
Key financial metrics include Q4 operating expenses of $2.3M (up from $1.3M in Q4 2024), a Q4 net loss of $2.1M, and cash position of $11.6M as of June 30, 2025. The company secured a $994,300 grant from NIDA to support their ongoing SAD study.
Additionally, Anebulo announced plans for a reverse stock split as part of a proposed going private transaction, aimed at maintaining fewer than 300 record holders to avoid SEC reporting requirements.
Anebulo Pharmaceuticals (Nasdaq: ANEB) has initiated dosing in its Phase 1 single ascending dose (SAD) study of intravenous selonabant for acute cannabis-induced toxicity. The study, supported by a $994,300 NIDA collaborative grant, aims to develop the first emergency antidote for cannabis toxicity.
The company is prioritizing the IV formulation specifically for pediatric patients, following successful Phase 2 trials of oral selonabant in adults. This strategic focus stems from children's heightened sensitivity to cannabis toxicity, which can lead to severe complications including CNS depression, respiratory depression, coma, and potentially death.
The FDA has indicated strong interest in collaborating with Anebulo to address this growing unmet medical need in pediatric cannabis toxicity treatment.
Anebulo Pharmaceuticals (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on cannabinoid-induced toxicities treatments, has provided an update on its previously announced going private transaction from July 23, 2025. The company has received interest from potential financial and strategic partners, prompting the Board to review all strategic alternatives.
The strategic options under consideration include the proposed going private transaction and reverse stock split, a potential sale of company assets, and possible merger transactions. While this review is ongoing, Anebulo plans to proceed with a special stockholder meeting to vote on the proposed reverse stock split, though the Board maintains discretion to abandon the split even if approved.
Anebulo Pharmaceuticals (Nasdaq: ANEB) has announced plans to go private through a significant reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500. The company will pay $3.50 per pre-split share in cash for fractional shares, representing a 91% premium over the July 22, 2025 closing price.
Stockholders holding fewer than the minimum number of shares (between 2,500 and 7,500) will be cashed out, while larger holders will receive one post-split share for every minimum number of pre-split shares. The company cites burdensome costs of being a public reporting company as the primary reason for this decision, aiming to focus on product development and cost reduction.